Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

FDA advisory committee recommends Ardelyx’s Xphozah for chronic kidney disease

The phase 3 trials supporting the submission met all primary and key secondary endpoints

- PMLiVE

University of Birmingham to launch type 1 diabetes trial for at-risk children

Blood tests will identify those deemed most likely to develop the condition

- PMLiVE

Adopting a holistic approach in crafting a product’s value story: utilising HEOR and RWE throughout the product life cycle

By Gary Schneider, Koen Degeling and Kathy Belk

- PMLiVE

ORIGINS INSIGHTS EVOLVES INTO PATIENT SPECIALIST AGENCY

Deeper focus on patient engagement across the pharma/biotech product lifecycle

Origins – The Patient Focused Specialists

- PMLiVE

Mark Corbett explains why Origins is evolving

Resonant Group Chief Innovation Officer, Mark Corbett has released a video explain why Origins is evolving from a Patient Insights agency to a Patient Focused Specialist agency.

Origins – The Patient Focused Specialists

- PMLiVE

Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine

Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants

- PMLiVE

Roche enters into second collaboration with Jnana to address complex drug targets

The Boston-based biotech will receive an upfront payment of $50m

- PMLiVE

FDA approves ImmunoGen’s Elahere for platinum-resistant ovarian cancer

An overall response rate of 31.7% was demonstrated, including five complete responses

- PMLiVE

NICE publishes draft guidance recommending three COVID-19 treatments

Five treatments have not been recommended for use, with the organisation citing cost-effectiveness concerns

- PMLiVE

The power of mentoring: creating connections

By Kerri Bednarcik and Nicki Davison

- PMLiVE

WHO, WIPO and WTO to hold technical symposium on pandemic preparedness

The event will examine ways to build resilience to be better prepared for future pandemics

- PMLiVE

AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza

The treatments are for use in prostate, biliary tract and advanced gastric cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links